H epatoblastoma is the most common liver tumor in childhood, accounting for over 50% of liver masses and about 67% of malignant liver neoplasms (1) . Like most solids tumors, hepatoblastoma requires neovascularization for growth and metastasis. Hepatoblastoma expresses several proangiogenic factors, including vascular endothelial growth factor (VEGF) (2) , hepatocyte growth factor (HGF) (3) , and IGF-II (4, 5) , whose expression and/or signaling are modulated by hypoxia (6 -10) . Intratumoral hypoxia can shift the balance between endogenous proangiogenic and antiangiogenic factors, thus leading to the excessive neovascularization of the growing tumor mass. Several studies have focused on characterizing hepatoblastoma-derived angiogenesis inducers, whereas very little is known about the endogenous inhibitors. Any decreased expression of inhibitory factors would also be expected to contribute to a proangiogenic environment, thus favoring hepatoblastoma growth.
Development of antiangiogenic therapies for cancer is an area of active research (11) (12) (13) . Treatments targeting the endothelial cells may have the advantage in that their antitumor effect does not result in the acquired drug resistance that arises with conventional therapies that target the genetically unstable tumor cells, a current problem in some treatment regimens of hepatoblastoma (14, 15) . In vivo models of hepatoblastoma have shown that therapeutic strategies focusing on blocking angiogenesis such as anti-VEGF antibody (16) and the angiogenic inhibitor TNP-470 (17) resulted in restricted tumor growth by inhibiting new vessel formation. Loss of critical endogenous inhibitors of angiogenesis may also contribute to the pro-angiogenic microenvironment in hepatoblastoma (18, 19) ; thus, replacement therapy may restore the angiogenic balance.
PEDF is a 50 kD protein that is a potent inhibitor of angiogenesis (20) and is expressed at high levels in normal hepatocytes and liver parenchymal cells (21, 22) . Purified recombinant PEDF protein has been shown to inhibit the effects of several inducers of angiogenesis on endothelial cells including, VEGF, aFGF (fibroblast growth factor), bFGF, IL-8, lysophosphatidic acid, and platelet-derived growth factor (20) . In addition, expression of PEDF is sensitive to hypoxia in retinoblastoma cells (20) and some prostate-derived cells (23) . We postulated that loss of PEDF in the hepatoblastoma tumor microenvironment leads to excessive neovascularization, and, thus, restoring the endogenous inhibitor PEDF by gene trans-Tumor harvest and immunohistochemistry. The subcutaneous tumors were harvested, weighed, measured, and tumor volume calculated using the formula length ϫ width (2) ϫ 0.52 as described (26) . Portions of the tumor tissue were washed five times in sterile PBS, minced, and incubated in serum-free media for 48 h and CM collected as above. The remainder of the tumor tissue was formalin-fixed and paraffin embedded for histologic examination.
Histologic sections of tumor tissue were stained for PEDF, MVD, and VEGF using an affinity purified anti-PEDF antibody (20) , anti-factor VIII related antigen antibody (R & D Systems, Minneapolis, MN), and anti-VEGF antibody (R & D Systems), respectively. Sections of tissue were dried at 42°C for 24 h and deparaffinized, incubated at room temperature with primary antibody, followed by incubation with an avidin-biotin peroxidase-conjugated secondary antibody, signal developed with diaminobenzidine, and counterstained with hematoxylin. Negative controls were run during each staining procedure. Routine hematoxylin and eosin (H&E) staining was performed on each tissue section.
MVD and mitotic figures were compared between the Hyb-PEDF and Hyb-␤gal experimental groups. Using anti-factor VIII related antigen antibody stained sections; the number of endothelial-lined vessels within the tumor were counted in 5 hpf by two independent reviewers. A brown stain was considered positive and the values were expressed as mean number of vessels per hpf Ϯ SEM. Using H&E-stained tissue, mitotic figures were assessed in 5 hpf and values expressed as mean number of mitoses per hpf Ϯ SEM. VEGF staining intensity was graded on a scale of 1 (absent to minimal staining) to 4 (intense staining) and compared between treatment groups.
Statistical analysis. Statistical significance of data were determined by using unpaired t tests; p values of Ͻ0.05 were considered statistically significant.
RESULTS
PEDF secreted by hepatoblastoma cells is a hypoxiasensitive and functional angiogenic mediator. To determine whether the human hepatoblastoma cell line, HUH-6, secreted PEDF, serum-free CM were analyzed by immunoblot. Under normoxic conditions, the HUH-6 cells secreted PEDF as evidenced by the intense band at 50 kD (Fig. 1A, lane 2) . However, when HUH-6 cell CM were collected in the presence of 100 M cobalt chloride, a chemical treatment that (23), PEDF levels were decreased by 65% compared with untreated (Fig. 1A , lane 1 versus lane 2). To assess whether the PEDF secreted by the hepatoblastoma cells was a functional angiogenesis inhibitor, CM collected under normoxic conditions from HUH-6 cells was examined using an in vitro microvascular endothelial cell migration assay, an assay that correlates well with in vivo angiogenic activity (23) . The secretions from the HUH-6 cells were angiogenic as determined by their ability to induce endothelial migration 4-fold over the BSA baseline control (Fig. 2) . To assess whether VEGF was an active inducer secreted by HUH-6 cells, we added an anti-VEGF antibody, which resulted in a decrease in endothelial cell migration (Fig.  2) , however, these results did not reach statistical significance, suggesting that other inducers also contribute to the high angiogenic activity. However, addition of an antibody that neutralizes the angio-inhibitory activity of PEDF resulted in a significant increase in cell migration (p Ͻ 0.05), thus demonstrating that the PEDF secreted by HUH-6 cells does function as an angiogenesis inhibitor.
Gene transfer of PEDF suppresses tumor growth. Subcutaneous tumors were induced in athymic mice using 3 ϫ 10 6 HUH-6 cells. All animals thrived during the treatment period. Animals bearing tumors 5 mm in diameter were randomized into treatment groups. There was no significant difference in tumor volumes between those tumors receiving no treatment and those treated with Hyb-␤gal (p ϭ 0.52; Fig. 3 ). In contrast, tumors treated with Hyb-PEDF had a significantly lower tumor volume compared with the Hyb-␤gal treated tumors (d 7 mean ϭ 97.67 Ϯ 9.8 versus 248 Ϯ 28.3; p Ͻ 0.008, Fig. 3 ). Histologic examination revealed that the tumors treated with Hyb-PEDF had more differentiated tumor cells characterized by diminished nuclear to cytoplasmic ratios and a tendency to form trabecula. Hyb-PEDF tumors also had confluent areas of necrosis. In contrast, the tumors harvested for the Hyb-␤gal treatment group had sheets of pleomorphic tumor cells with atypical mitoses and minimal to no necrosis.
To compare the levels of PEDF produced by the untreated and Hyb-␤gal-and Hyb-PEDF-treated tumors, tumor tissue was minced, and CM was collected and evaluated by immunoblot analysis. Interestingly, the levels of PEDF produced by the untreated and the Hyb-␤gal treated tumors were lower than what would have been predicted by the level produced by the parental cells, at ϳ32% and 6% the level of the cells grown in vitro (Fig. 1 , compare lanes 3 and 5 to lane 2), suggesting that growth in vivo selected for HUH-6 cells secreting low levels of PEDF or that the in vivo growth conditions down-regulate PEDF expression. The CM of the Hyb-PEDF treated tumors expressed levels equivalent to the cells grown in vitro and ϳ3-fold higher levels of PEDF than the untreated tumors and almost 20-fold higher than the Hyb-␤gal tumor CM (Fig. 1 , compare lane 4 to lane 5), demonstrating that PEDF expression was higher and persistent in the Hyb-PEDF tumors. The uptake of the virus in the Hyb-␤gal-treated tumors was verified by ␤-galactosidase staining (data not shown). Fig. 5, A-C) . PCNA staining showed a similar fold decrease in the Hyb-PEDF group (data not shown). These results suggest that altering the vasculature of a tumor affected the proliferative capacity of the tumor epithelial cells.
Hyb-PEDF treatment resulted in decreased VEGF expression. To determine whether changes in PEDF might affect other hypoxia-sensitive angiogenic mediators such as VEGF, immunohistochemistry for PEDF and VEGF expression was performed on tumor tissue from each group. As expected, PEDF staining was most intense in the Hyb-PEDF treatment group with strong positivity within tumor cells and in the surrounding interstitial tissue. This was in contrast to the weak staining for PEDF observed in the Hyb-␤gal-treated tumors (Fig. 6, A and B) . Staining with anti-VEGF antibodies also revealed striking differences between the treatment groups. This staining was quantified by grading on a scale of 1-4. There was intense positivity for VEGF in the Hyb-␤gal-treated tumors, with a mean staining value of 2.75 Ϯ 0.47 (n ϭ 4), and weak staining for the VEGF in the Hyb-PEDFtreated tumors, with a mean staining value of 1.25 Ϯ 0.25 (n ϭ 4; p Ͻ 0.03; Fig. 6, C and D) . This suggests that PEDF treatment may directly or indirectly down-regulate VEGF in vivo.
DISCUSSION
Hepatoblastoma, like most solid tumors, is dependent on pathologic neovascularization for growth and metastasis (27) .
In this study, we demonstrated a loss of a potent inhibitor of 
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PEDF SUPPRESSES HEPATOBLASTOMA TUMORS angiogenesis, PEDF, in hepatoblastoma in vivo. This study established that forced overexpression of PEDF via gene transfer was able to limit experimental tumor growth. Decreased levels of VEGF and reduced microvascularity may be two mechanisms underlying the altered growth. We found that PEDF expression by human hepatoblastoma cell line (HUH-6) was dramatically decreased under hypoxic conditions and in vivo growth by hepatoblastoma correlated with lower levels of PEDF. Additionally, the baseline angiogenic activity of the HUH-6 was significantly increased when exposed to an anti-PEDF antibody suggesting that reduction or loss of endogenous PEDF removes a barrier to growth of the tumor vasculature.
PEDF is a 50 kD multifunctional protein that is found at high levels in the retina, placenta, prostate, kidney, and liver (28, 29) . Initially labeled as a neurotrophic and neuroprotective factor, PEDF has been recognized as one of the most potent anti-angiogenic factors (15) , with a demonstrated ability to inhibit the growth of several cancers in vivo (30 -33) . As an endogenous inhibitor of angiogenesis, PEDF appears to target only new vessel formation (34) and is stable and nontoxic when administered as a soluble protein or by viral-mediated gene transfer (30, 32, 35) . By only targeting new sprouting vessels, PEDF would not be expected to alter native vasculature. In addition, this type of therapy would not be expected to select for drug-resistance genes that are known to exist in many cancers including hepatoblastoma.
Intratumoral hypoxia can trigger a cascade of tumorpromoting factors. VEGF, HGF, and IGF II are all hypoxiasensitive angiogenic inducers found in hepatoblastoma (2) (3) (4) (5) . Therapeutic treatment strategies targeting VEGF has been performed with moderate success (16) . However, antiangiogenic therapy directed against a single angiogenic inducer may have limited effect due to the presence of numerous inducers within a tumor mass (24) . In this study, we demonstrate that PEDF is also hypoxia sensitive in hepatoblastoma, similar to other tumor epithelial cells tested (20, 23) . The decrease in PEDF expression when tumor cells are exposed to cobalt chloride has also been noted in tumor cell lines derived for hepatocellular carcinoma (33) and prostate cancer (23) . This implies that, under hypoxic conditions, a common environmental state within tumor masses, a rise in VEGF can accompany a decrease in PEDF resulting in higher net angiogenic activity. An unexpected benefit of PEDF therapy was decreased expression of VEGF within the hepatoblastoma tumor. VEGF has been demonstrated to play a major role in hepatoblastomas growth and metastasis (2) . The ratio of PEDF to VEGF has been shown to be important in angiogenesisbased diseases, with a low ratio seen in retinal disease, melanoma, and neuroblastoma (32, 36, 37) . Our results suggest that a higher PEDF to VEGF ratio restricts hepatoblastoma growth, and suggests that PEDF may regulate neovascularization and tumor growth by suppressing VEGF's activities in addition to acting directly on the endothelial cell.
Gene therapy has been advocated as a potential antiangiogenic therapy delivery system for several reasons (38) . It allows for low-frequency dosing with sustained therapy production by the infected cells. Intratumoral gene therapy allows for selective expression by tumor cells resulting in higher local concentrations within the tumor while maintaining lower systemic levels limiting the number of adverse reactions (38) . After several consecutive administrations of our hybrid vector, its expression remained high for several days after the last dose. Further studies are needed to assess the effect of alternate dosing schedules, and the persistence of PEDF expression within treated tumors.
Therapeutic replacement of inhibitors such as PEDF has the distinct advantage of counteracting the stimulating endothelial cell activities of a wide array of angiogenic inducers (20) . In experimental models, PEDF shows minimal toxicity, spares normal cells from unnecessary death, and targets both endothelial and tumor epithelial cells. Development of new therapeutic avenues with agents like PEDF may provide hope for those children with chemo-resistant or inoperable hepatoblastoma tumors.
